Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zofin for COPD
NCT05643729Phase 2Suspended
- Sponsor
- Organicell Regenerative Medicine
- Start
- Nov 2023
- Primary completion
- May 2024
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of zofin in chronic obstructive pulmonary disease (COPD), sponsored by Organicell Regenerative Medicine. Started Nov 2023; status: suspended.
02
Drugs
zofin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05643729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643729.